Results 41 to 50 of about 14,967 (152)
Platelets, 2022 It remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in ...
Yue Wang +8 more
doaj +1 more source
The potential for biased signalling in the P2Y receptor family of GPCRs
British Journal of Pharmacology, EarlyView.The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk +2 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 Background Ticagrelor is a P2Y12 receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin.
Sukhdeep S. Basra +12 more
doaj +1 more source
The Lancet Regional Health. Europe, 2022 Summary: Background: Ticagrelor was introduced in Denmark in 2011 after randomised data showed its superiority over clopidogrel for patients with acute coronary syndrome (ACS). We assessed the effectiveness and safety of ticagrelor implementation in ACS
Pernille Gro Thrane +10 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Network meta‐analysis (NMA) enables the simultaneous comparison of multiple treatments by combining direct and indirect evidence across a network of studies. While its application is rapidly expanding in pharmacological research and clinical guideline development, performing NMA typically requires advanced statistical knowledge ...
János Tibor Fekete +2 more
wiley +1 more source
Early Mobilization After Pacemaker Implantation
Pacing and Clinical Electrophysiology, EarlyView.ABSTRACT Background The increasing use of cardiac implantable electronic devices (CIED) is leading to a rise in procedure‐related complications. Objective This trial aimed to assess the safety and feasibility of early mobilization and the possibility of same‐day discharge following permanent pacemaker implantation.
Jiří Šmíd +3 more
wiley +1 more source
Journal of Interventional Cardiology, 2023 Background. Dual antiplatelet therapy with a P2Y12 inhibitor (e.g., clopidogrel and ticagrelor) and aspirin is recommended for at least one year after percutaneous coronary intervention (PCI) to prevent further myocardial infarction and stent thrombosis ...
Mohammadjavad Mehdizadeh Parizi +12 more
doaj +1 more source
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
BMC Cardiovascular Disorders, 2018 Background & Aims Ticagrelor has been acknowledged as a new oral antagonist of P2Y12-adenosine diphosphate receptor, as a strategy with more rapid onset as well as more significant platelet inhibition function in acute coronary syndrome (ACS) patients ...
Dong Wang +5 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 928-941, April 2026.From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park +22 more
wiley +1 more source
Кардиоваскулярная терапия и профилактикаIn patients with chronic coronary syndrome, ticagrelor decreases cardiovascular events more efficiently than clopidogrel. In several studies investigating novel P2Y12 inhibitors dyspnea has been detected.
Dunya Habeeb Shnain +2 more
doaj +1 more source